Who
Moshe Arkin
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, Odysight.ai; 10% owner, Werewolf Therapeutics; Vice Chairman, Perrigo Co; Insider, NeurogesX; Other, Orexigen Therapeutics.
In numbers
- Trades disclosed
- 1,090
- Buys
- 3
- Sells
- 95
- Bought
- $13.8M
- Sold
- $287.0M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 16 Aug 2006
- Last trade
- 20 Aug 2026
- Last filed
- 24 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 24 Aug 2026 | ODYS Odysight.aiIT Services & Consulting | SEC FORM 4 Bought | $3.6M1,125,000 at $3.20 | filing |
| 20 Aug 2026filed 24 Aug 2026 | ODYS Odysight.aiIT Services & Consulting | SEC FORM 4 Bought | $3.6M1,125,000 at $3.20 | filing |
| 25 Mar 2026filed 27 Mar 2026 | ODYS Odysight.aiIT Services & Consulting | SEC FORM 4 Code M | $12.9M2,352,941 at $5.50 | filing |
| 25 Mar 2026filed 27 Mar 2026 | ODYS Odysight.aiIT Services & Consulting | SEC FORM 4 Code F | $11.4M2,081,044 at $5.50 | filing |
| 25 Mar 2026filed 27 Mar 2026 | ODYS Odysight.aioption or derivative · IT Services & Consulting | SEC FORM 4 Code M | —2,352,941 at $0.00 | filing |
| 25 Mar 2026filed 27 Mar 2026 | ODYS Odysight.aioption or derivative · IT Services & Consulting | SEC FORM 4 Code M | —2,352,941 at $0.00 | filing |
| 25 Mar 2026filed 27 Mar 2026 | ODYS Odysight.aiIT Services & Consulting | SEC FORM 4 Code M | $12.9M2,352,941 at $5.50 | filing |
| 25 Mar 2026filed 27 Mar 2026 | ODYS Odysight.aiIT Services & Consulting | SEC FORM 4 Code F | $11.4M2,081,044 at $5.50 | filing |
| 4 May 2021filed 4 May 2021 | HOWL Werewolf Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —10,714,284 at $0.00 | filing |
| 4 May 2021filed 4 May 2021 | HOWL Werewolf Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,560,551 at $0.00 | filing |
| 4 May 2021filed 4 May 2021 | HOWL Werewolf TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,235,917 | filing |
| 4 May 2021filed 4 May 2021 | HOWL Werewolf TherapeuticsBiotechnology | SEC FORM 4 Code C | —410,717 | filing |
| 4 May 2021filed 4 May 2021 | HOWL Werewolf TherapeuticsBiotechnology | SEC FORM 4 Bought | $6.4M400,000 at $16.00 | filing |
| 31 Aug 2011filed 2 Sep 2011 | Perrigo Co | SEC FORM 4 Sold | $1.3M13,549 at $94.55 | filing |
| 31 Aug 2011filed 2 Sep 2011 | Perrigo Co | SEC FORM 4 Sold | $1.3M13,715 at $95.18 | filing |
| 31 Aug 2011filed 2 Sep 2011 | Perrigo Co | SEC FORM 4 Sold | $5.1M52,591 at $96.20 | filing |
| 30 Aug 2011filed 1 Sep 2011 | Perrigo Co | SEC FORM 4 Sold | $16.4M170,145 at $96.46 | filing |
| 27 Jun 2011filed 28 Jun 2011 | NeurogesX | SEC FORM 4 Sold | $2,2661,079 at $2.10 | filing |
| 24 Jun 2011filed 28 Jun 2011 | NeurogesX | SEC FORM 4 Sold | $16K7,499 at $2.10 | filing |
| 20 May 2011filed 24 May 2011 | Perrigo Co | SEC FORM 4 Sold | $35K400 at $87.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
No headline names them, or the companies they trade most, lately.